Deposition of GBM invasion chip data to the Microphysiology Systems Database

Information

  • Research Project
  • 10382952
  • ApplicationId
    10382952
  • Core Project Number
    R15GM132877
  • Full Project Number
    3R15GM132877-01S1
  • Serial Number
    132877
  • FOA Number
    PA-20-272
  • Sub Project Id
  • Project Start Date
    5/1/2021 - 4 years ago
  • Project End Date
    4/30/2022 - 3 years ago
  • Program Officer Name
    BRAZHNIK, PAUL
  • Budget Start Date
    5/1/2021 - 4 years ago
  • Budget End Date
    4/30/2022 - 3 years ago
  • Fiscal Year
    2021
  • Support Year
    01
  • Suffix
    S1
  • Award Notice Date
    9/13/2021 - 3 years ago
Organizations

Deposition of GBM invasion chip data to the Microphysiology Systems Database

PROJECT SUMMARY Glioblastoma (GBM) is the most prevalent and aggressive primary malignant brain tumor. The patient median survival is only fifteen months, due to its chemotactic invasion into adjacent brain tissues through the 3D-confined interstitial space. The underlying mechanism is still poorly understood, and effective therapies are still lacking. This is due to the lack of adequate research platforms. There is currently no representation of this disease in the Microphysiology System Database. Through an active NIH grant study, we recently developed a microfluidic device to study GBM invasion. This device recapitulates the native environment for individual cancer cell migration through interstitial space. We further integrated the chemical perfusion system that can manipulate the chemotactic environment (e.g., chemical composition, absolute concentration, concentration gradient) in real-time. So far, we have collected a significant amount of cell images and migration data, in various chemotactic conditions. We also collected the pharmacokinetic data for a potential inhibitory drug. To render the data to the general public, we propose to re-format and deposit them in the Microphysiology System Database. We will also expand the dataset by collecting the pharmacokinetic data from additional patient-derived cell lines. This study's outcome will significantly enhance our understanding of the GBM invasion and promote the discovery of more effective therapy.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R15
  • Administering IC
    GM
  • Application Type
    3
  • Direct Cost Amount
    35000
  • Indirect Cost Amount
    15640
  • Total Cost
    50640
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    859
  • Ed Inst. Type
    BIOMED ENGR/COL ENGR/ENGR STA
  • Funding ICs
    NCATS:50640\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
  • Study Section Name
  • Organization Name
    UTAH STATE UNIVERSITY
  • Organization Department
    ENGINEERING (ALL TYPES)
  • Organization DUNS
    072983455
  • Organization City
    LOGAN
  • Organization State
    UT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    843221415
  • Organization District
    UNITED STATES